BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(11): 1900-1912 [PMID: 38077640 DOI: 10.4251/wjgo.v15.i11.1900]
URL: https://www.wjgnet.com/1007-9327/full/v15/i11/1900.htm
Number Citing Articles
1
Qian Wang, Tingting Wu, Ru Zhao, Yuanqin Li, Xuetao Chen, Shanmei Shen, Xiaowen Zhang. Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During ImmunotherapyEndocrine Practice 2024;  doi: 10.1016/j.eprac.2024.07.006
2
Qiu-Yu Jiang, Ru-Yi Xue. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse eventsWorld Journal of Gastrointestinal Oncology 2024; 16(3): 577-582 doi: 10.4251/wjgo.v16.i3.577
3
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint InhibitorsCancers 2024; 16(6): 1225 doi: 10.3390/cancers16061225
4
Zhenli Li, Tiezhu Yao, Guang Liu, Zhengkun Guan, Jing Liu, Ling Guo, Jingtao Ma. Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysisJournal of Cancer Research and Clinical Oncology 2024; 150(5) doi: 10.1007/s00432-024-05801-7
5
Qiang Zhao, Liang Wang, Xun Yang, Jifeng Feng, Qixun Chen. Association of the Scottish inflammatory prognostic score with treatment-related adverse events and prognosis in esophageal cancer receiving neoadjuvant immunochemotherapyFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1418286